Sanofi's sales jumped 14.3% last quarter, and the company raised its expectations for the whole year.

Oct 30, 2026, 4:51 AM ETResultsRead the original at morningstar.com

Good for SNY

Sanofi raised its sales and profit forecasts after sales grew, led by Dupixent. Its search for acquisitions ahead of patent expirations signals a pipeline need, but no deal was announced.

SNY · Sanofi

AI read · Good for SNY

The AI's read

The stronger sales and profit expectations point to continued demand, led by Dupixent. That gives Sanofi a stronger base for the year. Sanofi is also seeking acquisitions as patent expirations approach. This signals a need to refresh its medicine pipeline, but no deal was announced.

Get alerts for SNY

Follow Sanofi (SNY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SNY

Free on the App Store and Google Play, or on the web.